Khan, O. F., Alvi, M. A., Salluzzi, M., Bridges, R., Watson, A. S., Torres, F. S., Leighl, N. B., Riskas, J., Haider, S. A., Sivan, V., Samorodova, O., Hennessy, T. J., Shah, D., Curtis, M., Baldauf-Lenschen, F. (2026). Association between depth of IPRO-α response and overall survival (OS) in patients with advanced non–small cell lung cancer (aNSCLC) treated with first-line (1L) pembrolizumab monotherapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e20521